Adakveo is manufactured by Novartis under the name Ryverna for emerging markets.
Manufacturer: Novartis Pharma GmbH Roonstrasse 25 90429 Nuremberg Germany
Information about ADAKVEO
Adakveo (crizanlizumab-tmca) is a medication used for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD). Treatment use for adult and 16 year old people.
After 1st dose, 2 dose will after 2 week then all dose followed by every 4 weeks. If missed any dose immediately contact your doctor.
Product Highlights
- Medication used for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD).
- Treatment usage for 16 years of age and older people.
- After 1st dose, 2 doses will after 2 week.
- Then all dose you will be given an every 4 weeks.
Key Ingredients
Key Benefits
- Reduction in VOC Frequency.
- Improvement in Pain Management
- Potential for Better Disease Management.
- Continual use of Adakveo as part of a treatment regimen may lead to sustained improvement in symptoms and overall health outcomes for patients with SCD.
- Treatment Option for a Specific people.
- Potential side effects, Adakveo has been shown to have a manageable safety profile in clinical trials.
Direction for Use
- After 1st dose, 2 dose will after 2 week then all dose followed by every 4 weeks. If missed any dose immediately contact your doctor.
Safety Concern
- If missed any dose immediately contact your doctor.
Avoid Taking ADAKVEO If:
- You have an allergy to ADAKVEO.
- The packaging is torn or has signs of tampering.
- The medicine has expired as it may not work if taken after the expiry date.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
